GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » 3-Year FCF Growth Rate

Immunotech Biopharm (HKSE:06978) 3-Year FCF Growth Rate : 24.10% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm 3-Year FCF Growth Rate?

Immunotech Biopharm's Free Cash Flow per Share for the six months ended in Dec. 2023 was HK$-0.18.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 24.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -20.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 6 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Immunotech Biopharm was 24.10% per year. The lowest was -79.30% per year. And the median was -32.50% per year.


Competitive Comparison of Immunotech Biopharm's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Immunotech Biopharm's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunotech Biopharm's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Immunotech Biopharm's 3-Year FCF Growth Rate falls into.



Immunotech Biopharm 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Immunotech Biopharm  (HKSE:06978) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Immunotech Biopharm 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunotech Biopharm (HKSE:06978) Business Description

Traded in Other Exchanges
N/A
Address
No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Executives
Jung Hyun Chul
Evodevo Ltd
Tian Jin He Yue Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Wu Naifeng 2501 Other
Yan Kaijing 2501 Other
Yan Xijun 2501 Other
Tian Shi Li Kong Gu Ji Tuan You Xian Gong Si 2501 Other
Tian Shi Li Yi Yao Ji Tuan Gu Fen You Xian Gong Si 2501 Other
Tian Jin Di Zhi Tou Zi Guan Li You Xian Gong Si 2501 Other
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si 2501 Other
Li Yunhui 2501 Other
Tian Jin Hong Xun Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Kang Shun Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Shan Zhen Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Shun Qi Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other

Immunotech Biopharm (HKSE:06978) Headlines

No Headlines